Cargando…

Electrochemical Detection of Alzheimer’s Disease Biomarker, β-Secretase Enzyme (BACE1), With One-Step Synthesized Reduced Graphene Oxide

β-Secretase1 (BACE1) catalyzes the rate-limiting step in the generation of amyloid-β peptides, that is, the principal component involved in the pathology of Alzheimer’s disease (AD). Recent research studies show correlation between blood and cerebrospinal fluid (CSF) levels of BACE1 with the pathoph...

Descripción completa

Detalles Bibliográficos
Autores principales: Dey, Jhilik, Roberts, Akanksha, Mahari, Subhasis, Gandhi, Sonu, Tripathi, Prem Prakash
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8987718/
https://www.ncbi.nlm.nih.gov/pubmed/35402415
http://dx.doi.org/10.3389/fbioe.2022.873811
_version_ 1784682803833602048
author Dey, Jhilik
Roberts, Akanksha
Mahari, Subhasis
Gandhi, Sonu
Tripathi, Prem Prakash
author_facet Dey, Jhilik
Roberts, Akanksha
Mahari, Subhasis
Gandhi, Sonu
Tripathi, Prem Prakash
author_sort Dey, Jhilik
collection PubMed
description β-Secretase1 (BACE1) catalyzes the rate-limiting step in the generation of amyloid-β peptides, that is, the principal component involved in the pathology of Alzheimer’s disease (AD). Recent research studies show correlation between blood and cerebrospinal fluid (CSF) levels of BACE1 with the pathophysiology of AD. In this study, we report one-step synthesized reduced graphene oxide (rGO), activated via carbodiimide chemistry, conjugated with BACE1 antibody (Ab), and immobilized on fluorine-doped tin oxide (FTO) electrodes for rapid detection of BACE1 antigen (Ag) for AD diagnosis. The synthesis and fabrication steps were characterized using different types of spectroscopic, X-ray analytic, microscopic, and voltametric techniques. Various parameters including nanomaterial/Ab concentration, response time, pH, temperature, and rate of scan were standardized for maximum current output using the modified electrode. Final validation was performed via detection of BACE1 Ag ranging from 1 fM to 1 µM, with a detection limit of 0.64 fM in buffer samples and 1 fM in spiked serum samples, as well as negligible cross-reactivity with neurofilament Ag in buffer, spiked serum, and spiked artificial CSF. The proposed immunosensor gave a quick result in 30 s, and good repeatability and storage stability for a month, making it a promising candidate for sensitive, specific, and early diagnosis of AD. Thus, the fabricated electrochemical biosensor for BACE-1 detection improves detection performance compared to existing sensors as well as reduces detection time and cost, signifying its potential in early diagnosis of AD in clinical samples.
format Online
Article
Text
id pubmed-8987718
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89877182022-04-08 Electrochemical Detection of Alzheimer’s Disease Biomarker, β-Secretase Enzyme (BACE1), With One-Step Synthesized Reduced Graphene Oxide Dey, Jhilik Roberts, Akanksha Mahari, Subhasis Gandhi, Sonu Tripathi, Prem Prakash Front Bioeng Biotechnol Bioengineering and Biotechnology β-Secretase1 (BACE1) catalyzes the rate-limiting step in the generation of amyloid-β peptides, that is, the principal component involved in the pathology of Alzheimer’s disease (AD). Recent research studies show correlation between blood and cerebrospinal fluid (CSF) levels of BACE1 with the pathophysiology of AD. In this study, we report one-step synthesized reduced graphene oxide (rGO), activated via carbodiimide chemistry, conjugated with BACE1 antibody (Ab), and immobilized on fluorine-doped tin oxide (FTO) electrodes for rapid detection of BACE1 antigen (Ag) for AD diagnosis. The synthesis and fabrication steps were characterized using different types of spectroscopic, X-ray analytic, microscopic, and voltametric techniques. Various parameters including nanomaterial/Ab concentration, response time, pH, temperature, and rate of scan were standardized for maximum current output using the modified electrode. Final validation was performed via detection of BACE1 Ag ranging from 1 fM to 1 µM, with a detection limit of 0.64 fM in buffer samples and 1 fM in spiked serum samples, as well as negligible cross-reactivity with neurofilament Ag in buffer, spiked serum, and spiked artificial CSF. The proposed immunosensor gave a quick result in 30 s, and good repeatability and storage stability for a month, making it a promising candidate for sensitive, specific, and early diagnosis of AD. Thus, the fabricated electrochemical biosensor for BACE-1 detection improves detection performance compared to existing sensors as well as reduces detection time and cost, signifying its potential in early diagnosis of AD in clinical samples. Frontiers Media S.A. 2022-03-24 /pmc/articles/PMC8987718/ /pubmed/35402415 http://dx.doi.org/10.3389/fbioe.2022.873811 Text en Copyright © 2022 Dey, Roberts, Mahari, Gandhi and Tripathi. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Bioengineering and Biotechnology
Dey, Jhilik
Roberts, Akanksha
Mahari, Subhasis
Gandhi, Sonu
Tripathi, Prem Prakash
Electrochemical Detection of Alzheimer’s Disease Biomarker, β-Secretase Enzyme (BACE1), With One-Step Synthesized Reduced Graphene Oxide
title Electrochemical Detection of Alzheimer’s Disease Biomarker, β-Secretase Enzyme (BACE1), With One-Step Synthesized Reduced Graphene Oxide
title_full Electrochemical Detection of Alzheimer’s Disease Biomarker, β-Secretase Enzyme (BACE1), With One-Step Synthesized Reduced Graphene Oxide
title_fullStr Electrochemical Detection of Alzheimer’s Disease Biomarker, β-Secretase Enzyme (BACE1), With One-Step Synthesized Reduced Graphene Oxide
title_full_unstemmed Electrochemical Detection of Alzheimer’s Disease Biomarker, β-Secretase Enzyme (BACE1), With One-Step Synthesized Reduced Graphene Oxide
title_short Electrochemical Detection of Alzheimer’s Disease Biomarker, β-Secretase Enzyme (BACE1), With One-Step Synthesized Reduced Graphene Oxide
title_sort electrochemical detection of alzheimer’s disease biomarker, β-secretase enzyme (bace1), with one-step synthesized reduced graphene oxide
topic Bioengineering and Biotechnology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8987718/
https://www.ncbi.nlm.nih.gov/pubmed/35402415
http://dx.doi.org/10.3389/fbioe.2022.873811
work_keys_str_mv AT deyjhilik electrochemicaldetectionofalzheimersdiseasebiomarkerbsecretaseenzymebace1withonestepsynthesizedreducedgrapheneoxide
AT robertsakanksha electrochemicaldetectionofalzheimersdiseasebiomarkerbsecretaseenzymebace1withonestepsynthesizedreducedgrapheneoxide
AT maharisubhasis electrochemicaldetectionofalzheimersdiseasebiomarkerbsecretaseenzymebace1withonestepsynthesizedreducedgrapheneoxide
AT gandhisonu electrochemicaldetectionofalzheimersdiseasebiomarkerbsecretaseenzymebace1withonestepsynthesizedreducedgrapheneoxide
AT tripathipremprakash electrochemicaldetectionofalzheimersdiseasebiomarkerbsecretaseenzymebace1withonestepsynthesizedreducedgrapheneoxide